Report Information More information from: https ://www.wis eguyreports .com/reports /495872
Gliosarcoma - Pipeline Review, H1 2016 Report / Search Code: WGR495872
Price
1-user P DF : $ 2000.0
Description:
Publish Date: 11 May, 2016
Site P DF : $ 4000.0
Enterprise P DF : $ 6000.0
Glios arcoma - Pipeline Review, H1 2016 Summary Global Markets Direct’s , ‘Glios arcoma - Pipeline Review, H1 2016’, provides an overview of the Glios arcoma pipeline lands cape. The report provides comprehens ive information on the therapeutics under development for Glios arcoma, complete with analys is by s tage of development, drug target, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type. The report als o covers the des criptive pharmacological action of the therapeutics , its complete res earch and development his tory and lates t news and pres s releas es . Additionally, the report provides an overview of key players involved in therapeutic development for Glios arcoma and features dormant and dis continued projects . Global Markets Direct’s report features inves tigational drugs from acros s globe covering over 20 therapy areas and nearly 3,000 indications . The report is built us ing data and information s ourced from Global Markets Direct’s proprietary databas es , company/univers ity webs ites , clinical trial regis tries , conferences , SEC filings , inves tor pres entations and featured pres s releas es from company/univers ity s ites and indus try-s pecific third party s ources . Drug profiles featured in the report undergoes periodic review following a s tringent s et of proces s es to ens ure that all the profiles are updated with the lates t s et of information. Additionally, various dynamic tracking proces s es ens ure that the mos t recent developments are captured on a real time bas is . The report helps in identifying and tracking emerging players in the market and their portfolios , enhances decis ion making capabilities and helps to create effective counter s trategies to gain competitive advantage. Note*: Certain s ections in the report may be removed or altered bas ed on the availability and relevance of data. Scope - The report provides a s naps hot of the global therapeutic lands cape of Glios arcoma - The report reviews pipeline therapeutics for Glios arcoma by companies and univers ities /res earch ins titutes bas ed on information derived from company and indus try-s pecific s ources - The report covers pipeline products bas ed on various s tages of development ranging from pre-regis tration till dis covery and undis clos ed s tages - The report features des criptive drug profiles for the pipeline products which includes , product des cription, des criptive MoA, R& D brief, licens ing and collaboration details & other developmental activities - The report reviews key players involved Glios arcoma therapeutics and enlis ts all their major and minor projects - The report as s es s es Glios arcoma therapeutics bas ed on drug target, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type - The report s ummarizes all the dormant and dis continued pipeline projects - The report reviews lates t news related to pipeline therapeutics for Glios arcoma Reas ons to buy - Gain s trategically s ignificant competitor information, analys is , and ins ights to formulate effective R& D s trategies - Identify emerging players with potentially s trong product portfolio and create effective counter-s trategies to gain competitive advantage - Identify and unders tand important and divers e types of therapeutics under development for Glios arcoma - Identify potential new clients or partners in the target demographic - Develop s trategic initiatives by unders tanding the focus areas of leading companies - Plan mergers and acquis itions effectively by identifying key players and it’s mos t promis ing pipeline therapeutics - Devis e corrective meas ures for pipeline projects by unders tanding Glios arcoma
pipeline depth and focus of Indication therapeutics - Develop and des ign in-licens ing and out-licens ing s trategies by identifying pros pective partners with the mos t attractive projects to enhance and expand bus ines s potential and s cope - Modify the therapeutic portfolio by identifying dis continued projects and unders tanding the factors that drove them from pipeline Contents:
Table of Contents Table of Contents 2 Lis t of Tables 5 Lis t of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Glios arcoma Overview 7 Therapeutics Development 8 Pipeline Products for Glios arcoma - Overview 8 Pipeline Products for Glios arcoma - Comparative Analys is 9 Glios arcoma - Therapeutics under Development by Companies 10 Glios arcoma - Therapeutics under Inves tigation by Univers ities /Ins titutes 11 Glios arcoma - Pipeline Products Glance 12 Clinical Stage Products 12 Glios arcoma - Products under Development by Companies 13 Glios arcoma - Products under Inves tigation by Univers ities /Ins titutes 14 Glios arcoma - Companies Involved in Therapeutics Development 15 Amgen Inc. 15 Axelar AB 16 Burzyns ki Res earch Ins titute, Inc. 17 Celgene Corporation 18 ERC Belgium SA 19 Merck & Co., Inc. 20 Millennium Pharmaceuticals , Inc. 21 NewLink Genetics Corporation 22 Novartis AG 23 Progenics Pharmaceuticals , Inc. 24 Glios arcoma - Therapeutics As s es s ment 25 As s es s ment by Monotherapy Products 25 As s es s ment by Combination Products 26 As s es s ment by Target 27 As s es s ment by Mechanis m of Action 29 As s es s ment by Route of Adminis tration 31 As s es s ment by Molecule Type 33 Drug Profiles 35 alis ertib - Drug Profile 35 Product Des cription 35 Mechanis m of Action 35 R& D Progres s 35 Antineoplas ton Therapy - Drug Profile 40 Product Des cription 40 Mechanis m of Action 40 R& D Progres s 40 AXL-1717 - Drug Profile 42 Product Des cription 42 Mechanis m of Action 42 R& D Progres s 42 CC-122 - Drug Profile 44 Product Des cription 44 Mechanis m of Action 44 R& D Progres s 44 DNX-2401 - Drug Profile 46 Product Des cription 46 Mechanis m of Action 46 R& D Progres s 46 ERC-1671 - Drug Profile 49 Product Des cription 49 Mechanis m of Action 49 R& D Progres s 49 flucytos ine + TBio-01 - Drug Profile 51 Product Des cription 51 Mechanis m of Action 51 R& D Progres s 51 indoximod - Drug Profile 53 Product Des cription 53 Mechanis m of Action 53 R& D Progres s 53 irinotecan hydrochloride + TBio-02 - Drug Profile 56 Product Des cription 56 Mechanis m of Action 56
R& D Progres s 56 lonafarnib - Drug Profile 58 Product Des cription 58 Mechanis m of Action 58 R& D Progres s 58 Oncolytic Virus to Target IL-12 for Oncology - Drug Profile 60 Product Des cription 60 Mechanis m of Action 60 R& D Progres s 60 p28 - Drug Profile 61 Product Des cription 61 Mechanis m of Action 61 R& D Progres s 61 pazopanib hydrochloride - Drug Profile 63 Product Des cription 63 Mechanis m of Action 63 R& D Progres s 63 PSMA ADC - Drug Profile 69 Product Des cription 69 Mechanis m of Action 69 R& D Progres s 69 rilotumumab - Drug Profile 71 Product Des cription 71 Mechanis m of Action 71 R& D Progres s 71 Glios arcoma - Recent Pipeline Updates 73 Glios arcoma - Dormant Projects 88 Glios arcoma - Product Development Miles tones 89 Featured News & Pres s Releas es 89 Nov 26, 2013: Burzyns ki Clinic Pres ents the Succes s ful Treatment of a Child with Recurrent Diffus e Intrins ic Pontine Glios arcoma at the Congres s 89 Appendix 90 Methodology 90 Coverage 90 Secondary Res earch 90 Primary Res earch 90 Expert Panel Validation 90 Contact Us 90 Dis claimer 91 Lis t of Tables Number of Products under Development for Glios arcoma, H1 2016 8 Number of Products under Development for Glios arcoma - Comparative Analys is , H1 2016 9 Number of Products under Development by Companies , H1 2016 10 Number of Products under Inves tigation by Univers ities /Ins titutes , H1 2016 11 Comparative Analys is by Clinical Stage Development, H1 2016 12 Products under Development by Companies , H1 2016 13 Products under Inves tigation by Univers ities /Ins titutes , H1 2016 14 Glios arcoma - Pipeline by Amgen Inc., H1 2016 15 Glios arcoma - Pipeline by Axelar AB, H1 2016 16 Glios arcoma - Pipeline by Burzyns ki Res earch Ins titute, Inc., H1 2016 17 Glios arcoma - Pipeline by Celgene Corporation, H1 2016 18 Glios arcoma - Pipeline by ERC Belgium SA, H1 2016 19 Glios arcoma - Pipeline by Merck & Co., Inc., H1 2016 20 Glios arcoma - Pipeline by Millennium Pharmaceuticals , Inc., H1 2016 21 Glios arcoma - Pipeline by NewLink Genetics Corporation, H1 2016 22 Glios arcoma - Pipeline by Novartis AG, H1 2016 23 Glios arcoma - Pipeline by Progenics Pharmaceuticals , Inc., H1 2016 24 As s es s ment by Monotherapy Products , H1 2016 25 As s es s ment by Combination Products , H1 2016 26 Number of Products by Stage and Target, H1 2016 28 Number of Products by Stage and Mechanis m of Action, H1 2016 30 Number of Products by Stage and Route of Adminis tration, H1 2016 32 Number of Products by Stage and Molecule Type, H1 2016 34 Glios arcoma Therapeutics - Recent Pipeline Updates , H1 2016 73 Glios arcoma - Dormant Projects , H1 2016 88 Lis t of Figures Number of Products under Development for Glios arcoma, H1 2016 8 Number of Products under Development for Glios arcoma - Comparative Analys is , H1 2016 9 Number of Products under Development by Companies , H1 2016 10 Comparative Analys is by Clinical Stage Development, H1 2016 12 As s es s ment by Monotherapy Products , H1 2016 25 As s es s ment by Combination Products , H1 2016 26 Number of Products by Top 10 Targets , H1 2016 27 Number of Products by Stage and Top 10 Targets , H1 2016 27 Number of Products by Top 10 Mechanis m of Actions , H1 2016 29 Number of Products by Stage and Top 10 Mechanis m of Actions , H1 2016 29
Number Number Number Number
of of of of
Products Products Products Products
by by by by
Routes of Adminis tration, H1 2016 31 Stage and Routes of Adminis tration, H1 2016 31 Molecule Types , H1 2016 33 Stage and Molecule Types , H1 2016 33
wis eguyreports .com / Phone (US) + 1-646-845-9349 (UK) +44 208 133 9349